

# Shinji Takeuchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4205252/publications.pdf>

Version: 2024-02-01

48  
papers

1,618  
citations

361296

20  
h-index

302012

39  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2419  
citing authors

#	ARTICLE	IF	CITATIONS
1	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	5.8	223
2	Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2011-2017.	0.5	196
3	EGFR-TKI Resistance Due to <i>BIM</i> Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. <i>Cancer Research</i> , 2013, 73, 2428-2434.	0.4	151
4	Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2012, 18, 3592-3602.	3.2	104
5	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of <i>ALK</i> Mutation Status. <i>Cancer Research</i> , 2019, 79, 1658-1670.	0.4	79
6	Histone Deacetylase 3 Inhibition Overcomes <i>BIM</i> Deletion Polymorphism-Mediated Osimertinib Resistance in <i>EGFR</i> -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3139-3149.	3.2	69
7	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. <i>Nature Communications</i> , 2020, 11, 4607.	5.8	69
8	Notch3-dependent $\beta$ -catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. <i>Nature Communications</i> , 2018, 9, 3198.	5.8	61
9	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i> -mutant lung cancer cells. <i>Oncotarget</i> , 2016, 7, 3847-3856.	0.8	56
10	Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1034-1043.	1.9	55
11	<i>MET</i> Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of <i>EGFR</i> -mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 506-515.	1.9	52
12	Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors. <i>PLoS ONE</i> , 2013, 8, e84700.	1.1	41
13	<i>In vivo</i> imaging models of bone and brain metastases and pleural carcinomatosis with a novel human <i>EML4-ALK</i> lung cancer cell line. <i>Cancer Science</i> , 2015, 106, 244-252.	1.7	32
14	Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. <i>Cancer Science</i> , 2019, 110, 3215-3224.	1.7	32
15	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 140-146.	0.9	32
16	Phase I study of vorinostat with gefitinib in <i>BIM</i> deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. <i>Cancer Science</i> , 2020, 111, 561-570.	1.7	31
17	Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib-resistance of <i>EML4-ALK</i> lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , 2017, 108, 53-60.	1.7	28
18	Foretinib Overcomes Entrectinib Resistance Associated with the <i>NTRK1</i> G667C Mutation in <i>NTRK1</i> Fusion-Positive Tumor Cells in a Brain Metastasis Model. <i>Clinical Cancer Research</i> , 2018, 24, 2357-2369.	3.2	25

#	ARTICLE	IF	CITATIONS
19	Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 752-765.	0.5	24
20	Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression. <i>Clinical Cancer Research</i> , 2021, 27, 1410-1420.	3.2	24
21	Impact of MET inhibition on small cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. <i>Cancer Science</i> , 2017, 108, 1378-1385.	1.7	20
22	Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer. <i>Cancer Science</i> , 2020, 111, 2374-2384.	1.7	17
23	Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma. <i>Cancer Research</i> , 2015, 75, 4188-4197.	0.4	16
24	Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 317-320.	0.2	16
25	Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance. <i>Respiratory Investigation</i> , 2014, 52, 348-356.	0.9	15
26	Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. <i>Cancer Science</i> , 2017, 108, 696-703.	1.7	15
27	Organ-specific efficacy of HSP90 inhibitor in multiple organ metastasis model of chemorefractory small cell lung cancer. <i>International Journal of Cancer</i> , 2016, 138, 1281-1289.	2.3	14
28	Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 947-956.	1.9	14
29	Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021, 10, 314-325.	1.3	13
30	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. <i>BMC Pulmonary Medicine</i> , 2018, 18, 193.	0.8	12
31	Trametinib overcomes KRAS G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer. <i>Cancer Science</i> , 2021, 112, 3784-3795.	1.7	12
32	In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. <i>Oncotarget</i> , 2017, 8, 73766-73773.	0.8	10
33	MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. <i>Cancer Science</i> , 2020, 111, 3813-3823.	1.7	9
34	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis. <i>Npj Precision Oncology</i> , 2022, 6, 11.	2.3	8
35	Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 321-325.	0.2	7
36	Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases. <i>Anticancer Research</i> , 2019, 39, 5449-5459.	0.5	6

#	ARTICLE	IF	CITATIONS
37	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. <i>BMC Cancer</i> , 2020, 20, 156.	1.1	6
38	Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1009-1014.	1.0	6
39	Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of <i>NTRK1</i> -rearranged tumor cells. <i>Cancer Science</i> , 2022, 113, 2323-2335.	1.7	5
40	Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with <i>BIM</i> deletion polymorphism. <i>Journal of Medical Investigation</i> , 2020, 67, 343-350.	0.2	3
41	Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. <i>Internal Medicine</i> , 2022, 61, 1735-1738.	0.3	3
42	<i>In vivo</i> imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. <i>Cancer Medicine</i> , 2017, 6, 2972-2983.	1.3	2
43	Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. <i>Oxford Medical Case Reports</i> , 2020, 2020, oaa116.	0.2	2
44	Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. <i>Molecular and Clinical Oncology</i> , 2016, 4, 537-540.	0.4	1
45	Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass. <i>Internal Medicine</i> , 2021, 60, 409-415.	0.3	1
46	Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 378-383.	0.3	1
47	Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab. <i>Internal Medicine</i> , 2022, 61, 75-79.	0.3	0
48	Development of Therapy for Overcoming EGFR-TKI Resistance due to <i>BIM</i> Polymorphisms. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 941-947.	0.0	0